Answers are grounded in this paper and cite their sources.
We conclude that CMV chemotherapy improves outcome as first-line adjunctive treatment for invasive bladder cancer. Two large randomized trials (by the Medical Research Council/European Organisation for Research and Treatment of Cancer and Southwest Oncology Group) have confirmed a statistically significant and clinically relevant survival benefit, and neoadjuvant chemotherapy followed by definitive local therapy should be viewed as state of the art, as compared with cystectomy or radiotherapy alone, for deeply invasive bladder cancer.
No takes yet. Share an insight, caveat, or question.
Gareth Griffiths (2011) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: